Contact

Per Fischer
CEO

pbf@minervax.com

Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark 

News
Main
Thursday
Jul172008

MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS).

GBS is the leading cause of life-threatening bacterial infections in newborn babies affecting some 8,000 babies annually in Europe and the US. GBS infections may result in still-births, or pneumonia, septicaemia and meningitis in the newborn babies leading to either severe morbidity, mortality or life-long disabilites. The National Institute of Health of the US has identified prevention of GBS in newborns as a major vaccine objective, but so far no approved or universally useful vaccine exists. A general vaccine effective against relevant strains of GBS is poised to have great impact and could potentially be administered to pregnant women or adolescent women as part of a general vaccine program.

PrintView Printer Friendly Version

EmailEmail Article to Friend